Furthermore, our data are in agreement with the fact that p120 is not haplo-insufficient in tumour suppression, and suggest that heterozygous genomic inactivation predisposes to complete loss of p120 expression and subsequent adverse survival of cancer patients. This evidence concerns the gene CTNND1 and neoplasm.